MicroQuin experiment makes it to the International Space Station

MicroQuin's protein study to be conducted on the ISS through a grant by CASIS/Boeing was launched on 7/25 aboard SpaceX CRS-18. Read more on NASA's press releases here and here, and watch the launch recording here.

Yang Zheng named a Crain's Chicago Business 20 in Their 20s

MicroQuin co-founder Yang Zheng was named one of the top young change-makers in Chicago of 2019 after building two biotech companies while finishing his MBA at Chicago Booth. 

MicroQuin and Scott Robinson's journey featured in Boston Globe

A glimpse into the journey that Dr. Robinson has been on to drive our technology to its current stage. Through series of personal sacrifice, Dr. Robinson has given the technology and company a chance to make a significant impact in patient lives.

MicroQuin joins prestigious LabCentral in Kendall Square, Cambridge

MicroQuin has been accepted into the highly competitive Lab Central.  We intend to continue our ground breaking research at this facility and strive to make significant advances in delivering first-in-class treatments for breast cancer.  Watch this space!

MicroQuin is going to space for studies in the International Space Station!

MicroQuin wins TWO grants from CASIS/BOEING under this year’s “Technology in Space” program. For the first time CASIS funded 2 projects from one company as part of its MassChallenge competition. These studies will be performed on the ISS and the data will have considerable impact on creating new scientific approaches to battling cancer.

MicroQuin was invited to present its ground-breaking technologies

MicroQuin was invited to showcase our high impact and transformational technology at Health Pioneers 2018.  The conference brings together decision-makers and innovators from the pharma, biotech, insurance and public health sectors to explore new ways to collaborate and pioneer. 

Health hub.jpg
MicroQuin is a winner of the Health Hub Vienna 2018 package

Health Hub Vienna is an acceleration program is managed by INiTS, Vienna’s high-tech incubator with an over 15-year track record of successfully developing start-ups in the life sciences.

Masschallenge logo.png
MicroQuin is a Top 26 Finalist of MassChallenge 

The 26 finalists were selected among the 128 early-stage ventures at MassChallenge Boston’s acceleration program in May. The selected companies will move into the final judging round of the MassChallenge Awards, where they’ll compete for shares of $1.5 million in equity-free prizes